Su Chia-Wei, Chiang Chih-Sheng, Li Wei-Ming, Hu Shang-Hsiu, Chen San-Yuan
Department of Materials Science & Engineering, National Chiao Tung University, Hsinchu, Taiwan.
Nanomedicine (Lond). 2014 Jul;9(10):1499-515. doi: 10.2217/nnm.14.97.
Combination therapy for cancer patients is an important standard of care protocol because it can elicit synergistic therapeutic effects and reduce systemic toxicity by simultaneously modulating multiple cell-signaling pathways and overcoming multidrug resistance. Nanocarriers are expected to play a major role in delivering multiple drugs to tumor tissues by overcoming biological barriers. However, especially considering the different physical chemistry of chemotherapeutic drugs, it is highly desirable to develop a codelivery nanocarrier for controlled and targeted delivery of both hydrophobic and hydrophilic drugs. This review reports the recent developments in various combinational drug delivery systems and the simultaneous use of combinational drug delivery systems with functional agents.
癌症患者的联合治疗是一种重要的标准治疗方案，因为它可以通过同时调节多个细胞信号通路并克服多药耐药性来产生协同治疗效果并降低全身毒性。纳米载体有望通过克服生物屏障在将多种药物递送至肿瘤组织方面发挥主要作用。然而，特别是考虑到化疗药物不同的物理化学性质，开发一种用于疏水和亲水药物的可控靶向共递送纳米载体是非常必要的。本文综述了各种联合药物递送系统的最新进展以及联合药物递送系统与功能试剂的同时使用情况。
